No
Non vérifié

Novo Nordisk A/S

Ce que nous écrivons

FinanceIndustrie pharmaceutiqueManagement/Organisation d'EntreprisePolitique ÉtrangèrePublicité/Marketing/Médias/Communication
10/08/2026
Industrie pharmaceutique
Management/Organisation d'Entreprise
Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI
1.00
05/08/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk wins Dutch court injunction protecting patients from unapproved, unlawful compounded semaglutide nasal spray
1.00
04/08/2026
Industrie pharmaceutique
Management/Organisation d'Entreprise
Politique Étrangère
Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook
1.00
04/08/2026
Industrie pharmaceutique
Politique Étrangère
Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026
1.00
31/07/2026
Industrie pharmaceutique
Politique Étrangère
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
1.00
21/07/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly
1.00
15/07/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Publicité/Marketing/Médias/Communication
Politique Étrangère
Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved
1.00
11/06/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk A/S: IT Security incident at Novo Nordisk
1.00
11/06/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
1.00
02/06/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0